Skip to main content

Table 4 Analysis of demographic, clinical, histological, molecular and therapeutic characteristics of patients treated with mastectomy and breast conservative therapy (BCT) (test Pearson Khi2)

From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer

Patients characteristics Mastectomy [n = 205] No (%) BCT [n = 39] No (%) p value
Age
   <40 48 (23.4%) 6 (15.4%) 0.268
   ≥40 157 (76.6%) 33 (84.6%)  
Menopausal status
   No 129 (67.5%) 23 (63.9%) 0.669
   Yes 62 (32.5%) 13 (36.1%)  
Side
   Right 48 (43.6%) 71 (53%) 0.146
   Left 62 (56.4%) 63 (47%)  
Histology
   DIC 183 (91.1%) 36 (100%) 0.062
   LIC 18 (9%) 0  
SBR
   I 13 (6.6%) 4 (10.5%) 0.53
   II 130 (65.7%) 26 (68.4%)  
   III 55 (27.8%) 8 (21.1%)  
Hormone receptors
ER
   Positive 120 (60.3%) 28 (71.8%) 0.877
   Negative 79 (39.7%) 11 (28.2%)  
PR
   Positive 61 (57.5%) 23 (59%) 0.877
   Negative 45 (42.5%) 16 (41%)  
Tumour
   pT1 25 (12.4%) 10 (25.6%) 0.003
   pT2 111 (55.2%) 27 (69.2%)  
   pT3 55 (27.4%) 2 (5.1%)  
   pT4 10 (5%) 0  
pN, axillary
   pN0 49 (23.9%) 11 (28.2%) 0.285
   pN1 57 (27.8%) 15 (38.5%)  
   pN2 63 (30.7%) 10 (25.6%)  
   pN3 36 (17.6%) 3 (7.7%)  
Protocol
   Anthracycline 89 (43.4%) 21 (53.8%) 0.23
   CMF 116 (56.6%) 18 (46.2%)  
Breast/thoracic wall irradiation
   Yes 194 (94.6%) 39 (100%) 0.139
   No 11 (5.4%) 0  
Prophylactic supraclavicular fossa radiotherapy
   Yes 193 (94.1%) 38 (97.4%) 0.402
   No 12 (5.9%) 1 (2.6%)  
Internal mammary radiotherapy
   Yes 195 (94.1%) 38 (97.4%) 0.523
   No 10 (5.9%) 1 (2.6%)  
Axillary radiotherapy
   Yes 42 (20.5%) 7 (17.9%) 0.717
   No 163 (79.5%) 32 (82.1%)  
  1. SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor